Abstract
Statistical Analysis Plan for TriMaster: Randomised Double-Blind Crossover study
of a DPP4 inhibitor, SGLT2 inhibitor and
thiazolidinedione as third line therapy in patients with
type 2 diabetes who have suboptimal glycaemic
control on dual therapy with metformin and a
sulphonylurea
